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BACKGROUND Micra is a leadless pacemaker that is implanted in the
right ventricle and provides rate response via a 3-axis accelerometer
(ACC). Custom software was developed to detect atrial contraction using the ACC enabling atrioventricular (AV) synchronous pacing.
OBJECTIVE The purpose of this study was to sense atrial contractions from the Micra ACC signal and provide AV synchronous pacing.
METHODS The Micra Accelerometer Sensor Sub-Study (MASS) and
MASS2 early feasibility studies showed intracardiac accelerations
related to atrial contraction can be measured via ACC in the Micra
leadless pacemaker. The Micra Atrial TRacking Using A Ventricular
AccELerometer (MARVEL) study was a prospective multicenter study
designed to characterize the closed-loop performance of an AV synchronous algorithm downloaded into previously implanted Micra devices. Atrioventricular synchrony (AVS) was measured during
30 minutes of rest and during VVI pacing. AVS was deﬁned as a P
wave visible on surface ECG followed by a ventricular event ,300 ms.
RESULTS A total of 64 patients completed the MARVEL study procedure at 12 centers in 9 countries. Patients were implanted with a

Micra for a median of 6.0 months (range 0–41.4). High-degree AV
block was present in 33 patients, whereas 31 had predominantly
intrinsic conduction during the study. Average AVS during AV algorithm pacing was 87.0% (95% conﬁdence interval 81.8%–90.9%),
80.0% in high-degree block patients and 94.4% in patients with
intrinsic conduction. AVS was signiﬁcantly greater (P ,.001) during
AV algorithm pacing compared to VVI in high-degree block patients,
whereas AVS was maintained in patients with intrinsic conduction.
CONCLUSION Accelerometer-based atrial sensing is feasible and
signiﬁcantly improves AVS in patients with AV block and a singlechamber leadless pacemaker implanted in the right ventricle.
KEYWORDS Accelerometer; Atrial contraction; Atrioventricular
block; Atrioventricular synchronous pacing; Leadless pacemaker
(Heart Rhythm 2018;15:1363–1371) © 2018 The Authors. Published by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction

Algorithm description

The introduction of the transvenous pacemaker transformed
the outcomes of patients with bradyarrhythmias. Since
then, evolution in pacemaker technology has concentrated
on device miniaturization and battery life extension. Yet, addressing the system size did not substantially affect the
complication risk associated with transvenous systems,
including infection, pneumothorax, hematoma, and lead
dislodgment.1,2 The recent introduction of the transcatheter
leadless pacemaker has dramatically reduced the risk for
major complications by .50%.3,4 In the Micra
Transcatheter Pacing Study, procedural success rate was
99.2%, and major complication rate was 4.0%; this low
rate of complication was conﬁrmed in the real-world
setting.3,5 Importantly, 1-year follow up of the Micra cohort
demonstrated an 82% reduction in the need for system revision compared to transvenous systems.6 With these promising results, there is increasing interest in expanding the
utilization of leadless pacing. However, the use of singlechamber pacemakers is limited to 14% of pacemaker implantations.7 This is largely because of the potential beneﬁts of
atrial pacing in patients with sinus node dysfunction (SND)
as well as the recognized beneﬁts of atrioventricular synchrony (AVS) in decreasing the incidence of pacemaker syndrome, improving stroke volume, and positively inﬂuencing
functional status and quality of life in patients with atrioventricular block (AVB).8–10 We conducted 3 clinical trials to
develop and evaluate the performance of a novel
downloadable algorithm for the Micra single-chamber ventricular leadless pacemaker, based on intracardiac accelerometer data. We report the development and performance of this
algorithm in successfully achieving AVS in a large proportion of patients with high-grade AVB and an implanted Micra
device.

Accelerometer signals collected from MASS/MASS2
patients demonstrated that 4 distinct segments of cardiac
activity were seen in the accelerometer signal (Figure 1,
bottom panel). These segments corresponded to isovolumic
contraction and mitral/tricuspid valve closure (A1), aortic/
pulmonic valve closure (A2), passive ventricular ﬁlling
(A3), and atrial contraction (A4). The systolic components
A1 and A2 have been previously reported.11 Accelerometer
segments A3 and A4 were associated with mitral valve
ﬂow E- and A-wave measurements. Based on these signals,
an AV synchronous algorithm was developed to provide a
VDD pacing mode. Speciﬁcally, blanking windows were
manually set by the clinician to reject detection of signals
in the accelerometer that were ventricular in origin (A1,
A2). Atrial contraction was detected when the ﬁltered and
rectiﬁed accelerometer signal exceeded 1 of 2 programmable
thresholds. Because the A3 and A4 signals can fuse, creating
larger accelerometer signals at higher sinus rates .80 bpm,
the algorithm includes 2 programmable thresholds: a larger
A3 threshold to detect fused A3/A4 and a lower A4 threshold
for detecting the A4 signal later in diastole.
If atrial contraction was detected (A4), an atrial marker
(AS) was output via telemetry, and a programmable AV interval was initiated. Because of the electromechanical delay
between the electrical P wave and the A4 signal on the accelerometer, the A4 VP was typically programmed to 10 ms.
The algorithm incorporated a rate smoothing feature designed to maintain AVS during intermittent A4 undersensing. If an atrial contraction (A4) was not detected, a
ventricular pace was delivered at a programmable rate
smoothed interval (typically 100 ms) longer than the median
R-R interval.

Patients and procedures

Methods
Study design
The purpose of the Micra Accelerometer Sensor Sub-Study
(MASS) and MASS2 studies were to characterize the intracardiac accelerometer signals from the implanted Micra device during various patient activities to assess the
feasibility of sensing atrial contraction from the accelerometer. Both MASS and MASS2 were prospective nonrandomized, multicenter clinical feasibility studies.
The Micra Atrial TRacking Using A Ventricular AccELerometer (MARVEL) study was an acute, prospective, nonrandomized, multicenter clinical feasibility study. The
primary aim of MARVEL was to test the feasibility of
providing AVS pacing in patients with AVB using the algorithm developed from MASS and MASS2 studies.
Each study’s protocol was approved by the ethics committee at each participating institution and associated national
and local regulatory agencies where applicable. All patients
provided written informed consent.

A substudy of the Micra Transcatheter Pacing Study, MASS
included patients who had completed their 12-month followup. The MASS study consisted of a single in-ofﬁce visit and
an optional overnight Holter monitor recording period. After
patient consent was obtained, software was downloaded into
the patient’s device allowing telemetry of the accelerometer
signal and marker channel to a Holter monitor. The patient
then performed a series of posture and maneuver tests while
accelerometer signal was collected from each of Micra’s 3
accelerometer vectors. After study participation, the downloadable software was removed.
Inclusion criteria for the MASS2 study were similar to the
MASS study with the addition of an exclusion criterion that
the patient was not in atrial ﬁbrillation (AF). The MASS2
study procedures were similar to the MASS study procedures
with the addition of echocardiographic recording after the
posture and maneuver testing.
The MARVEL study enrolled patients 18 years of age
with AVB and not in permanent atrial arrhythmia who
were previously implanted with a Micra device. After
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Before study exit, the Holter and investigational software
were removed.

Endpoints
For the MASS and MASS2 studies, the primary endpoint of
interest was the A4 amplitude associated with atrial contraction for each cardiac cycle during each posture, maneuver,
and vector combination.
For the MARVEL study, the primary endpoint was the
rate of AVS during the 30-minute resting period. An additional endpoint was the rate of atrial detection (A4). In patients with intrinsic AV conduction, AVS will be high
because of intact conduction, and the atrial detection provides
a better indication of performance of the atrial sensing.

Statistical analysis

Figure 1 Overview of the atrioventricular synchronous algorithm developed from MASS/MASS2 accelerometer signals. Top: Device marker channel and programmable A2 and A3 blanking windows. VE 5 end of A3
window. Middle: Accelerometer signal in relation to the ventricular event
(dashed green vertical lines) and A1, A2, A3, and A4 events. Bottom: Rectiﬁed accelerometer signal and A2 blanking period (solid horizontal green
bar). Two programmable thresholds for A4 detection are indicated by the
light blue line. The ﬁrst programmable threshold is greater than the second,
allowing for detection when the A3 and A4 signals fuse at higher heart rates.

consent was obtained and baseline procedures performed, an
investigational software implementation of the AV synchronous algorithm was downloaded into the patient’s implanted
device and a Holter monitor placed. Algorithm parameters,
including accelerometer vector, A2 blanking period, A3
end time, A3 threshold, and A4 threshold, were programmed
to optimize A4 detection while the patient sat or laid still. After parameter optimization, the patient performed a series of
posture maneuvers (supine, laying on left side, laying on
right side, sitting, and standing) and exercises (walking at a
normal and fast cadence). Additionally, each patient rested
in a supine or sitting position for approximately 30 minutes.
Echocardiography was performed while the AV synchronous
algorithm was programmed to adaptive mode (VDD pacing)
and monitor mode (VVI pacing). To assess stroke volume,
the left ventricular outﬂow tract velocity–time integral
(LVOT VTI) was measured in both modes. Patient participation in an overnight Holter recording period was optional.

MASS/MASS2
There was no a priori statistical justiﬁcation for the sample
size in the MASS/MASS2 studies, as the primary goal of
these studies was to collect accelerometer signals for algorithm development.
ECG, right ventricular electrogram, and intracardiac
accelerometer waveform were extracted from each Holter
data ﬁle and processed using custom MATLAB tools (MathWorks, Natick, MA). For each Holter recording and within
each cardiac cycle, an A4 sensing window was identiﬁed.
The peak-to-peak A4 amplitude was measured from this
signal within the A4 sensing window. In patients with
intrinsic conduction, the mean of the A4 amplitude was
computed for each posture, maneuver, and vector combination. A mixed effects linear model with 2 ﬁxed factors (vector
and posture) and 1 random factor (patient) was used to determine the impact of vector and posture on A4 amplitude
among patients with normal sinus function (intrinsic conduction) and infrequent pacing during the Holter recording
period.
MARVEL
A sample size of 50 usable Holter ﬁles was postulated to
allow the AVS percentage to be estimated with precision of
3.8% (ie, distance between lower and upper 95% conﬁdence
interval [CI]) during the 30-minute resting period based on
the following assumptions: (1) average within patient AVS
percentage was 90% with a standard deviation (SD) of
12% and (2) average patient heart rate was 656 5 bpm.
Similar to the MASS/MASS2 studies, surface ECG, right
ventricular electrogram, intracardiac accelerometer waveform, and device marker channel were extracted from each
Holter data ﬁle. A technician (blinded to the device marker
channel) identiﬁed P waves on the surface ECG signal. A
custom MATLAB script collated the timing of each
P wave, times corresponding to each posture and maneuver,
and timing for each device marker channel relative to the
beginning of the Holter recording. For each cardiac cycle,
the primary endpoint of AVS was considered met if the
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Table 1

Baseline and medical history of patients in MARVEL

Characteristics

Figure 2 A4 signal amplitude from patients with normal sinus function
and intrinsic conduction requiring infrequent pacing. Error bars represent
standard deviation. Units (g) on the y-axis represent acceleration. N ranged
from 22 in vector 3, left position, to 38 in vector 1, supine position.

timing of the ventricular marker was within 300 ms of the
P wave. Similarly, the atrial contraction was considered detected if the AS marker was before the ventricular marker
and within 300 ms of the P wave.
AVS percentage and atrial detection rates were computed
within each patient and posture/maneuver combination by
dividing the total number of cardiac cycles meeting each
endpoint by the number of cardiac cycles. Logistic regression
models using generalized estimating equations to account for
correlation in algorithm performance within patient were
used to estimate the performance of the AV synchronous
algorithm across all patients within each posture/maneuver.
AVS percentage between VVI pacing (measured during
echocardiogram in AV synchronous algorithm monitor
mode) and the 30-minute resting period were also compared
using logistic regression models utilizing generalized estimating equations among patients within each predominant
heart rhythm observed (AVB or intrinsic conduction). Linear
regression was used to characterize the association between
time since device implant and AVS and A4 detection rates.
A paired t test was used to compare LVOT VTI between
AV algorithm and VVI pacing. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) or R
(www.r-project.org).

Results
Early feasibility results (MASS/MASS2)
Seventy-ﬁve patients were enrolled in the MASS/MASS2
studies, of whom 66 had normal sinus function and 9 were
in AF. Mean age was 74 6 12 years. Mean time since Micra
implant was 13.6 months (range 0–35.5 months). Of these 75
patients, 39 had normal sinus function with intrinsic conduction and did not require frequent pacing during the monitoring period. Four distinct segments of cardiac activity
were seen in the accelerometer signal (A1, A2, A3, and
A4; Figure 1). Mean A4 amplitude varied across postures
and vectors (Figure 2). Speciﬁcally, A4 amplitude for vector
2 (longitudinal to device body) was signiﬁcantly larger than
for vector 1 (P ,.001) or vector 3 (P ,.001) (both radial to
device body). A4 amplitude was lowest in the standing position relative to the left side, right side, and supine positions

Age (years)
Mean 6 SD
Range
Female
Months from Micra implant
Mean 6 SD
Range
Comorbidities
Hypertension
Paroxysmal atrial ﬁbrillation
Diabetes
Coronary artery disease
Chronic obstructive pulmonary
disease
Device location
Apex
Septum
Right ventricular outﬂow tract
Not reported
Predominant rhythm during Holter
recording
2nd-/3rd-degree AVB
Intrinsic AV conduction

Enrolled
(n 5 70)

Usable Holter
(n 5 64)

71.3 6 15.1 72.0 6 14.4
24–92
30–92
24 (34)
20 (31)
11.6 6 12.3 11.5 6 12.4
0–41.4
0–41.4
41 (59)
14 (20)
17 (24)
16 (23)
5 (7)

38 (59)
11 (17)
16 (25)
15 (23)
5 (8)

19 (27)
47 (67)
2 (3)
2 (3)

16 (25)
46 (72)
2 (3)
0 (0)

NA
NA

33 (52)
32 (48)

Values are n (%) unless otherwise indicated.
AVB 5 atrioventricular block; MARVEL 5 Micra Atrial TRacking Using A
Ventricular AccELerometer study.

(P ,.05). These recordings from the MASS/MASS2 studies
were used to develop an algorithm to provide AV synchronous pacing.

MARVEL results
A total of 70 patients at 12 centers in Malaysia, Europe, and
the United States were enrolled in the MARVEL study. Of
these patients, 64 (91%) had usable Holter recordings and
were included in the analysis. Six patients were not included
in the analyses: 2 exited the study before AV synchronous algorithm download, 2 had no visible P waves on Holter recordings, 1 was discovered to be in AF after download, and
1 exited before performing all study procedures. Of the 64 patients with usable Holter data, 1 was studied twice because
that patient was willing to undergo procedures again at later
follow-up (1 day postimplant and 3 months postimplant). The
2 Holter datasets from this patient were analyzed and reported separately, unless otherwise speciﬁed. Patients with
usable Holter recordings were on average 72.0 6 14.4 years
old and had been implanted with their Micra device for
11.5 6 12.4 months (range 0–41.4 months) (Table 1). The
majority of patients (52%) had a predominant rhythm of
2nd- or 3rd-degree AVB during the Holter recording,
whereas 48% had intrinsic conduction. Most of the patients
with intrinsic conduction received their pacemaker for
episodic AVB and did not demonstrate AVB during the
study.
During the 30-minute resting period, 118,640 cardiac
cycles were evaluated across the 64 usable Holter recordings.

Downloaded for Anonymous User (n/a) at Baptist Health South Florida from ClinicalKey.com by Elsevier on October 26, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.

Chinitz et al

AV Synchronous Leadless Pacing

1367

Figure 3 AV synchronous pacing percentage during AV algorithm pacing vs VVI mode by predominant rhythm during rest. Gray lines indicate individual
patients. Dark blue line indicates average. Error bars represent 95% conﬁdence intervals. AV 5 atrioventricular.

rate and time since implant among all 64 patients (P 5 .654)
(Figure 4, right). However, the one patient studied twice had
an AVS percentage of 98.9% (1 day postimplant), which
decreased to 53.6% (3 months postimplant). At the second
visit, the patient had a sinus rate ,50 bpm and a lower A4
amplitude.
The rate smoothing operation of the AV algorithm
improved AVS percentages during intermittent A4 undersensing in AVB patients, allowing AVS percentages to
exceed the rate of A4 detection (80.0% vs 71.3%)
(Supplemental Figure S2).
During posture testing, average AVS percentages in the
33 patients with AVB ranged from 62.7% during fast walking
to 81.5% during sitting; in the 31 patients with intrinsic

The AVS percentage across 64 patients was 87.0% (95% CI
81.8%–90.9%) and ranged from 30.2%–100% for individual
patients, with 53 patients (83%) having an AVS percentage
.70% (Supplemental Figure S1). During AV algorithm
mode, patients with a predominant rhythm of AVB had a signiﬁcant increase in AVS percentage while resting compared
to VVI pacing (80.0% vs 37.5%; P ,.001), whereas AVS
was maintained in patients with intrinsic conduction
(94.4% vs 91.4%; P 5 .102) (Figure 3). Eleven patients
(9 with AVB and 2 with intrinsic conduction) had AVS percentages ,70% during rest (Table 2). There was no statistical
association between AVS percentage and time since implant
among the 33 patients with AVB (P 5 .757) (Figure 4, left).
Likewise, there was no association between the A4 detection

Table 2

Reasons for AV synchrony rates ,70% during rest

Patient

Predominant rhythm during Holter
monitoring

Synchrony during rest (%)

Reason for low synchrony

0002950105
4192011007
4192011003

AVB
AVB
AVB

30.2
32.7
47.9

0002950104
6100101002

AVB
Intrinsic AV conduction

52.8
52.8

4192011010

AVB

53.6

1480101004
0042050101
1470101005
4192011008
6100101003

Intrinsic AV conduction
AVB
AVB
AVB
AVB

54.7
55.8
56.7
60.7
63.3

Low-amplitude A4
Low-amplitude A4
Conservative algorithm settings: tracked
sinus rate 2:1
Sinus rate ,50 bpm
SND: high sinus rate variability
High PVC rate
Low amplitude A4
Sinus rate ,50 bpm
High PVC rate
Low-amplitude A4
Low-amplitude A4
Low-amplitude A4
Sinus rate .120 bpm

AV 5 atrioventricular; AVB 5 atrioventricular block; PVC 5 premature ventricular complex; SND 5 sinus node dysfunction.
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Figure 4 Relationship between time since implant and AV synchronous pacing percentage (left) and atrial detection rate (right). AV 5 atrioventricular;
CI 5 conﬁdence interval.

conduction, AVS percentages ranged from 84.0% (fast
walking) to 94.4% (resting) (Figure 5). AVS percentages
were lowest during maneuvers requiring activity, regardless
of predominant heart rhythm.
Of the 33 patients with a predominant rhythm of AVB, 31
had an echocardiogram available for analysis during AV algorithm and VVI pacing. LVOT VTI was signiﬁcantly higher
during AV algorithm pacing compared to VVI pacing
(23.9 vs 21.8 cm; P 5 .004) (Figure 6).
Evaluation of electrograms and ECGs in all 64 Holter
datasets revealed no pauses and no instances of pacemakermediated tachycardia during AV algorithm pacing. Addition-

ally, no adverse events related to the device or AV algorithm
pacing mode were reported during the study.

Discussion
The MARVEL study demonstrated the feasibility of tracking
atrial contractions and providing AVS using a mechanical
accelerometer-based sensor in the Micra ventricular pacemaker. Speciﬁcally, the average AVS percentage at rest
was 87%. In patients with high-grade AVB, AVS improved
from 37.5% to 80% when comparing VVI vs AV algorithm
mode. The presence of the algorithm had no detrimental

Figure 5 AV synchronous pacing percentage by maneuver. Blue indicates patients with a predominant rhythm of AV block during study. White indicates patients with a predominant rhythm of intrinsic conduction during study. Error bars represent 95% conﬁdence intervals. AV 5 atrioventricular.
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Figure 6 A: Example echo-Doppler LVOT showing VTI in a patient during VVI vs VDD pacing. B: LVOT VTI (cm) during VVI mode and AV algorithm
pacing modes in 31 patients with AV block and paired echocardiogram. Gray lines indicate individual patients. Dark blue line indicates average. Error bars represent 95% conﬁdence interval of mean. P value from paired t test. AV 5 atrioventricular; LVOT 5 left ventricular outﬂow tract; VTI 5 velocity–time integral.

impact on AVS in patients with intrinsic AV conduction. The
achievement of AVS had a demonstrable effect on stroke volume as measured by VTI on echocardiography. As expected,
SND, premature ventricular complexes, and low-amplitude
signals contributed to a lack of synchrony, although this
was evident in a relatively small number of patients.
The study demonstrated that AVS with this algorithm was
impacted by activity. Detection of the atrial signal during activity decreased as the patient’s heart rate increased, creating
fusion of the atrial and ventricular components of the accelerometer signal, and acceleration due to motion superimposing on the signal. AVS was not impacted by changes in
posture while at rest. In this circumstance, it is important to
consider that the loss of atrial synchrony is compensated
for by an increase in heart rate and ejection fraction during
exercise, particularly in patients with preserved left ventricular systolic function.12 In addition, the algorithm was designed to include a rate smoothing feature and
programmable blanking periods that frequently allowed for
the maintenance of AVS when A4 sensing was difﬁcult or

intermittent. This feature improved the rate of AVS by
approximately 9%.
The study included patients tested from the day after
device implant to 41 months after implantation, and the
data showed no association between the time of implant
and the achievement of AVS or the ability to sense the A4
signal, although these were not paired tests. There were no instances of pacemaker-mediated tachycardia or signiﬁcant
interruption in ventricular pacing resulting in symptomatic
pauses. All other safety issues were either minor or unrelated
to the device.
The literature and published guidelines support use of
single-chamber pacemakers in patients with AVB under
certain circumstances.13 These include infrequent need for
pacing, vascular access issues, sedentary patients, and
comorbidities likely to impact clinical outcomes. However,
this does not preclude the beneﬁt of AVS, if it can be
achieved safely in this population of patients. This provides
the opportunity for this patient population to beneﬁt from
AVS and increased stroke volume, reduction in pacemaker
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syndrome incidence, and improvement in functional status
and quality of life; however, this would require long-term
evaluation.14–16 The loss of AVS with increased levels of
activity may be a limitation of the algorithm. However, this
may be mitigated by the fact that cardiac output at higher
rates has been shown to be more dependent on heart rate
than AVS.17 Thus, rate responsive pacing (ie, VVIR) may
be an adequate option for patients when active. In addition,
it has been demonstrated that the symptoms of “pacemaker
syndrome” are usually seen at rest18 and are mostly related
to retrograde VA conduction, which primarily occurs when
the ventricular rate is substantially higher than the atrial
rate.19
Patients with lower AVS tended to have SND (manifesting primarily as sinus arrhythmia, sinus bradycardia, and
sinus tachycardia) or had low-amplitude A4 signals. Clearly
patients with persisting or permanent atrial arrhythmias
would not beneﬁt from implantation of these devices; furthermore, the A4 signal during AF will likely be low and not
detected, resulting in pacing near the lower rate. Loss of
AVS also occurred as a result of low-amplitude signals
measured by the accelerometer. The signals obtained from
the accelerometer can be complex, and setting up the algorithm will require knowledge of the cardiac components of
the accelerometer signal. Although multiple accelerometer
vectors were tested at the initial setup, some patients had
consistently low-amplitude signals or experienced variations
in A4 amplitude during the monitoring periods. It is conceivable that atrial contractility is a signiﬁcant factor in sensing
the A4 signal and achieving mechanical synchrony. It is
also reasonable to speculate that patients with poor atrial
contraction may not beneﬁt from AVS and that rate responsive pacing alone is adequate for this population of patients
with single-chamber leadless devices. It will be important
to understand the factors creating an impediment to achieving
AVS and aid the decision-making process for physicians
contemplating the appropriateness of implanting these devices.

Study limitations
The limitations of this study are related to the acute manual
download of the algorithm into patients already receiving
VVI pacing by an implanted Micra device. Furthermore,
the algorithm cannot be used chronically because new hardware will be required to efﬁciently process the accelerometer
signal for AVS and provide adequate longevity. The device
needs to be tested chronically on de novo patients throughout
the life of the device. Paired individual patient data are not yet
available to assess the maintenance of a high percentage of
synchrony over time. Although the acute safety data are
robust, long-term safety and individual patient tolerance to
variable loss of AVS remain unknown. In addition, this study
did not establish the percentage of AVS required to achieve
anticipated beneﬁts such as reduction in pacemaker syndrome, improvement in functional status and quality of life,
and augmentation of cardiac function. Finally, although the

true safety of leadless pacemaker implantation is somewhat
limited by the lack of a randomized trial, the available data
strongly suggest that the elimination of morbidity associated
with lead dislodgment, hematoma, prolonged hospitalizations, pneumothorax, and infections will remain most
signiﬁcant.

Conclusion
Accelerometer-based atrial sensing is feasible and signiﬁcantly improves AVS in patients with AV block and a
single-chamber leadless pacemaker implanted in the right
ventricle.
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